Recent Finacing
Recent Raise
Ciclofilin develops host-targeting cyclophilin-inhibitor antivirals (lead CPI-431-32) targeting HCV/HIV-1 and other viruses (HBV, HPV, coronaviruses), collaborating with Scripps/NIH; based in San Diego, R&D in Edmonton.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor